- Trials with a EudraCT protocol (1,969)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,969 result(s) found.
Displaying page 28 of 99.
EudraCT Number: 2021-002177-25 | Sponsor Protocol Number: 19-255-03 | Start Date*: 2021-11-08 | ||||||||||||||||||||||||||
Sponsor Name:Nektar Therapeutics | ||||||||||||||||||||||||||||
Full Title: A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 in Combination with Cetuximab as a Salvage Regimen for Solid Tumors | ||||||||||||||||||||||||||||
Medical condition: Relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal carcinoma (CRC) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003998-26 | Sponsor Protocol Number: GCT1044-01 | Start Date*: 2020-05-16 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1044 in subjects with malignant solid tumors | |||||||||||||
Medical condition: Malignant Solid Tumors, per protocol GCT1044-01 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000068-30 | Sponsor Protocol Number: ECT-001 | Start Date*: 2021-12-15 | |||||||||||
Sponsor Name:Ectin Research AB | |||||||||||||
Full Title: An open-label, multi-center, phase I/II study of MFA-370 in patients with metastatic urothelial cancer | |||||||||||||
Medical condition: Metastatic urothelial cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) LT (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005822-27 | Sponsor Protocol Number: BLU-945-1101 | Start Date*: 2021-10-22 | |||||||||||
Sponsor Name:Blueprint Medicines Corporation | |||||||||||||
Full Title: A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer | |||||||||||||
Medical condition: EGFR Mutant Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002768-32 | Sponsor Protocol Number: MM03 | Start Date*: 2009-06-08 | |||||||||||
Sponsor Name:Freistaat Bayern | |||||||||||||
Full Title: A prospective phase I/II, one-arm, one-stage multi-center, open label study of lenalidomide in combination with pioglitazone, dexamethasone and metronomic low-dose chemotherapy with treosulfan in p... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023062-40 | Sponsor Protocol Number: PRP-001 | Start Date*: 2011-04-19 | |||||||||||
Sponsor Name:Medivation, Inc. | |||||||||||||
Full Title: A Phase 1/2, First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered Talazoparib (BMN 673) in Patients with Advanced or Recurrent Solid Tumors | |||||||||||||
Medical condition: Advanced or recurrent solid tumors for which there is no accepted standard treatment or for which standard treatment has failed. Patients may also be eligible if they are unable or decline to unde... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003741-15 | Sponsor Protocol Number: MSC_apceth_101/1 | Start Date*: 2013-06-27 | |||||||||||
Sponsor Name:apceth GmbH & Co. KG | |||||||||||||
Full Title: Treatment of Advanced Gastrointestinal Cancer in a Phase I/II trial with modified autologous MSC_apceth_101. Open-label, multicentre, phase I/II. | |||||||||||||
Medical condition: Patients suffering from advanced, recurrent or metastatic gastrointestinal adenocarcinoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003785-14 | Sponsor Protocol Number: 200249 | Start Date*: 2014-03-03 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK-3475 in Subjects with Advanced Renal Cell Carcinoma | ||||||||||||||||||
Medical condition: Renal Cell Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-004108-20 | Sponsor Protocol Number: UMCN-AKF13.05 | Start Date*: 2014-03-17 | ||||||||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | ||||||||||||||||||
Full Title: Improving the tolerability of the oral targeted anti-cancer drug pazopanib by food intake (DIET) | ||||||||||||||||||
Medical condition: Patients who are treated or will be treated with pazopanib. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000376-26 | Sponsor Protocol Number: ZPL521/101 | Start Date*: 2016-05-09 | |||||||||||
Sponsor Name:Ziarco Pharma Ltd | |||||||||||||
Full Title: A Randomised, Adaptive Design, Double-Blind (3rd Party Open), Placebo Controlled, Sequential Group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Applica... | |||||||||||||
Medical condition: Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002209-39 | Sponsor Protocol Number: M14LTK | Start Date*: 2014-07-30 |
Sponsor Name:The Netherlands Cancer Institute | ||
Full Title: Phase I/II study with lapatinib plus trametinib in patients with metastatic KRAS mutant non-small cell lungcancer | ||
Medical condition: non-small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004680-39 | Sponsor Protocol Number: AUTO3-PA1 | Start Date*: 2017-06-21 | ||||||||||||||||
Sponsor Name:Autolus Limited | ||||||||||||||||||
Full Title: A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 in Paediatric and Adult Patients with R... | ||||||||||||||||||
Medical condition: Acute lymphoblastic leukaemia (ALL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004376-64 | Sponsor Protocol Number: EURO17-09 | Start Date*: 2018-01-10 | |||||||||||
Sponsor Name:Eurocine Vaccines AB | |||||||||||||
Full Title: A Phase I/II, randomised, multicentre, placebo-controlled, partially-blinded, parallel-group study to assess the safety, tolerability and immune response following vaccination with ImmunoseTM FLU i... | |||||||||||||
Medical condition: Influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001242-25 | Sponsor Protocol Number: BBT120126032001 | Start Date*: 2017-02-07 | ||||||||||||||||
Sponsor Name:Blueberry Therapeutics Ltd. | ||||||||||||||||||
Full Title: An Early Phase Development, Partly Blinded, Positive and Vehicle Controlled, Randomized, Non-inferiority Investigation of the Pharmacokinetics, Safety and Efficacy of BB2603 Cutaneous Hand-Pump Spr... | ||||||||||||||||||
Medical condition: Onychomycosis and associated Tinea Pedis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002641-29 | Sponsor Protocol Number: INCB57643-101 | Start Date*: 2018-03-20 | |||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||
Full Title: A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | |||||||||||||
Medical condition: Subjects with relapsed or refractory advanced or metastatic malignancies. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001417-79 | Sponsor Protocol Number: DIAGNODE-1 | Start Date*: 2018-02-05 | |||||||||||
Sponsor Name:Linköping University | |||||||||||||
Full Title: Open Label Pilot Trial in patients with recent-onset T1D to evaluate the safety, diabetes status and immune response of GAD-antigen (Diamyd®) therapy administered into lymph nodes in combination wi... | |||||||||||||
Medical condition: Type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005510-34 | Sponsor Protocol Number: MMV_DSM265_14_01 | Start Date*: 2015-09-30 | |||||||||||
Sponsor Name:Medicines for Malaria Venture | |||||||||||||
Full Title: Evaluation of the prophylactic antimalarial activity of a single dose of DSM265 in non-immune healthy adult volunteers by controlled human malaria infection with PfSPZ Challenge | |||||||||||||
Medical condition: Healthy volunteers; controlled human malaria infection with PfSPZ | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002327-29 | Sponsor Protocol Number: RGH-188-201 | Start Date*: 2017-01-05 | ||||||||||||||||
Sponsor Name:Gedeon Richter Plc. | ||||||||||||||||||
Full Title: Open-Label, Multicentre, Multiple Dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Cariprazine in Adolescent Subjects with Schizophrenia, Schizoaffective- and Schizophreniform Di... | ||||||||||||||||||
Medical condition: Schizophrenia, Schizoaffective- and Schizophreniform Disorders | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000700-26 | Sponsor Protocol Number: 178-CL-203 | Start Date*: 2015-09-23 | ||||||||||||||||
Sponsor Name:Astellas Pharma Europe B.V. | ||||||||||||||||||
Full Title: A multicentre, open-label, single dose, phase 1 study to evaluate the pharmacokinetics, safety and tolerability of mirabegron oral suspension in pediatric subjects from 3 to less than 12 years of a... | ||||||||||||||||||
Medical condition: -neurogenic detrusor overactivity (NDO) -overactive bladder (OAB) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-007553-31 | Sponsor Protocol Number: AMLSG10-07 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Phase I/II Clinical Study of SU11248 (Sutent) combined with Standard Chemotherapy with Cytosine Arabinoside and Daunorubicin in Patients with FLT3 mutated AML over 60 years of age | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
